Walgreens stock (NASDAQ:WBA) surged 18% on December 10 after stories emerged that it was being bought to a non-public fairness investor. Walgreens is probably going discussing a take care of New York-based Sycamore Companions that might shut early subsequent yr. Sycamore makes a speciality of shopper, distribution, and retail-related investments.
Walgreens has struggled these days as a result of declining prescription reimbursements and rising competitors from Amazon and different low cost shops. It has closed tons of of shops in recent times, and it plans to shut 1,200 shops by 2027 – a transfer necessitated by the truth that 1 / 4 of the corporate’s shops aren’t worthwhile. Individually, in order for you upside with a smoother journey than a person inventory, contemplate the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.
Moreover, there are direct-to-consumer telehealth and e-commerce platforms, which can supply medicine at decrease costs. Earlier this yr, Eli Lilly introduced that it could lower the costs for sure doses of its well-liked weight problems drug – Zepbound – if ordered instantly from Eli Lilly’s e-commerce platform. The brand new pricing for these doses might be 50% cheaper than the opposite GLP-1 medicine out there, though the lowered pricing received’t apply to the doses lined by insurance coverage. These components add to the woes of corporations like Walgreens and CVS.
Now, Walgreens not solely depends on pharmacy but additionally retail gross sales, and the components above indicate a decrease footfall, which is able to impression its retail gross sales as effectively. Walgreens has been centered on increasing its on-line and first care choices to assist income development. The VillageMD acquisition in 2021 was a step in that route. Nonetheless, VillageMD needed to shut operations at tons of of clinics to chop prices and increase profitability. Walgreens additionally ended up recording a $5.8 billion impairment cost associated to its VillageMD funding in fiscal 2024.
Walgreens tried to promote its worldwide chain – Boots – however determined to not proceed with the sale amid valuation points. Now, promoting to a non-public fairness agency bodes effectively for traders because the valuation supplied will probably be at a premium to the market worth. WBA inventory has taken a beating in the previous few years, with its market capitalization falling from roughly $50 billion in early 2022 to round $7.5 billion earlier this month.
Even after its latest 18% rise, WBA inventory is down 57% this yr. The lower in WBA inventory over the latest years has been removed from constant, with annual returns being extra unstable than the S&P 500. Returns for the inventory have been 36% in 2021, -25% in 2022, and -25% in 2023. In distinction, the Trefis High Quality (HQ) Portfolio, with a set of 30 shares, is way much less unstable. And it has outperformed the S&P 500 every year over the identical interval. Why is that? As a bunch, HQ Portfolio shares supplied higher returns with much less danger versus the benchmark index; much less of a roller-coaster journey, as evident in HQ Portfolio efficiency metrics.
We estimate Walgreens’ Valuation to be $14 per share, based mostly on 8x ahead anticipated adjusted earnings of $1.71 in fiscal 2025, under the inventory’s common P/E ratio of 10x over the past three years. A decline in valuation a number of appears justified, given the grim profitability outlook for Walgreens and the elevated competitors from direct e-commerce platforms.
Whereas WBA inventory has been on a decline, it’s useful to see how Walgreens’ Friends fare on metrics that matter. You will see different beneficial comparisons for corporations throughout industries at Peer Comparisons.
Returns | Dec 2024 MTD [1] |
2024 YTD [1] |
2017-24 Complete [2] |
WBA Return | 15% | -57% | -82% |
S&P 500 Return | 0% | 27% | 170% |
Trefis Strengthened Worth Portfolio | -1% | 23% | 817% |
[1] Returns as of 12/11/2024
[2] Cumulative complete returns because the finish of 2016
Make investments with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.